Alpha-fetoprotein (AFP) remains the most widely used serum biomarker in the management of hepatocellular carcinoma (HCC), the dominant form of primary liver cancer. Its clinical utility spans surveillance, diagnosis, prognostication, and treatment monitoring, while the recognition of its isoforms—AFP-L3 and PIVKA-II—and integrated scores such as GALAD have progressively refined its diagnostic precision. This review summarizes current knowledge of AFP biology, its isoforms, and the evolving landscape of HCC biomarker research, with a focus on how multi-analyte protein array platforms are accelerating translational advances. To support oncology and liver disease research, we provide flexible and reliable analysis services using protein array technology, meeting diverse needs in cytokine profiling, tumor-associated antigen detection, and biomarker discovery.
Introduction
Hepatocellular carcinoma accounts for the majority of primary liver cancer cases worldwide and ranks among the leading causes of cancer-related death, particularly in regions with high prevalence of chronic hepatitis B or C and metabolic liver disease. The prognosis of HCC is strongly tied to stage at diagnosis: tumors detected within established surveillance programs are more amenable to curative therapies such as resection, ablation, or transplantation, whereas symptomatic disease is frequently diagnosed at an advanced stage when treatment options are limited and survival is poor. This clinical reality has placed enormous weight on serum biomarkers, especially alpha-fetoprotein, as the cornerstone of non-invasive disease monitoring.
Since the first clinical description of elevated serum AFP in hepatocellular carcinoma more than half a century ago, our understanding of this protein has evolved from a single binary tumor marker into a more nuanced system that encompasses isoforms, glycoforms, and integrated scoring algorithms. Modern biomarker research now seeks to combine AFP with complementary analytes such as AFP-L3 and PIVKA-II, and to embed these markers within larger multiplex panels that capture the inflammatory and immunological context of liver disease. The shift from single-marker to multi-marker thinking is reshaping the diagnostic, prognostic, and therapeutic landscape of HCC.
Molecular Biology of Alpha-Fetoprotein
AFP is a 70 kDa glycoprotein that belongs to the albuminoid gene superfamily, sharing structural homology with serum albumin, vitamin D-binding protein, and alpha-albumin. During fetal development, AFP is the dominant serum protein produced by the yolk sac and the fetal liver, reaching peak concentrations around 12–16 weeks of gestation and declining to adult levels within the first year of life. In adults, AFP expression is largely silenced in healthy hepatocytes but can be reactivated under conditions of strong regenerative or oncogenic signaling, which explains its resurgence in both acute liver injury and hepatocellular carcinoma.
At the molecular level, AFP transcription is governed by a complex network of transcription factors, including HNF1, HNF4, FOXA, and p53, with the oncofetal reactivation of the AFP gene in HCC frequently associated with MYC activation and the loss of adult hepatocyte transcriptional programs. Once secreted, AFP exerts multiple biological effects that extend beyond its role as a passive tumor marker. It binds to a range of ligands, including fatty acids, bilirubin, retinoids, and metal ions, and influences cell proliferation, apoptosis, and immune signaling. The protein has been shown to interact with dendritic cells, T lymphocytes, and natural killer cells, contributing to the immunosuppressive tumor microenvironment that characterizes HCC.
These biological features have led to the concept of AFP as both a biomarker and an active oncoprotein. The same circulating glycoprotein that informs clinical decisions also participates in the pathophysiological processes that drive tumor progression, a duality that has stimulated growing interest in AFP-targeted therapies and in the development of assays capable of distinguishing biologically active isoforms from inert total protein measurements.
Figure 1. A model depicting how AFP regulating HCC progression. (Source: Chen T, et al. 2020)
Isoforms and Glycoform Variants: AFP-L3 and PIVKA-II
Although total AFP continues to be the most commonly measured analyte, it is now well established that AFP exists as a mixture of isoforms distinguished by their carbohydrate side chains and binding properties. The most clinically important isoform is AFP-L3, also known as the Lens culinaris agglutinin-reactive fraction of AFP. AFP-L3 carries an additional α1-6 fucose residue on the innermost N-acetylglucosamine of its biantennary glycan, a modification that confers preferential binding to the lectin Lens culinaris agglutinin. This fucosylated glycoform is produced at significantly higher rates by malignant hepatocytes than by benign or regenerating liver tissue, and the ratio of AFP-L3 to total AFP has been shown to improve specificity for HCC, particularly in patients with modestly elevated total AFP.
A second major complementary biomarker is PIVKA-II, also called des-γ-carboxy prothrombin (DCP), an abnormal prothrombin molecule generated as a consequence of defective vitamin K-dependent carboxylation in malignant hepatocytes. PIVKA-II is functionally distinct from AFP, has a different half-life, and is independently predictive of tumor aggressiveness, microvascular invasion, and poor prognosis. Combining PIVKA-II with AFP and AFP-L3 has been shown in multiple studies to improve the detection of early-stage HCC and to refine prognostic stratification beyond what is achievable with any single marker.
Importantly, AFP-L3 and PIVKA-II do not merely replicate the information conveyed by total AFP. Each marker reflects a different aspect of tumor biology: AFP-L3 captures the aberrant glycosylation associated with malignant transformation, while PIVKA-II reflects the dysfunctional biosynthetic environment of HCC cells. The complementary nature of these three biomarkers provides a strong conceptual rationale for their combined use, and forms the basis of integrated scoring systems such as the GALAD model.
Clinical Applications: Surveillance, Diagnosis, and Prognosis
AFP is most familiar in the context of HCC surveillance, where it is typically paired with biannual ultrasound in at-risk populations, including patients with cirrhosis, chronic hepatitis B or C, or advanced non-alcoholic fatty liver disease. While ultrasound alone has well-recognized limitations, particularly in obese patients and those with coarse cirrhotic liver echotexture, the addition of AFP consistently improves sensitivity for early-stage tumor detection, although the magnitude of improvement varies across studies and populations. The integration of AFP-L3 and PIVKA-II into surveillance protocols has been associated with further gains in sensitivity, especially for tumors within Milan criteria, although cost-effectiveness considerations vary between healthcare systems.
As a diagnostic marker, AFP has historically been incorporated into clinical algorithms that combine imaging features with tumor markers to stratify the probability of HCC. In contemporary guidelines, including those of the European Association for the Study of the Liver, AFP retains a role as an adjunct to imaging rather than a stand-alone diagnostic criterion, and the diagnostic cutoff values have been refined over time to balance sensitivity against false-positive elevations caused by active hepatitis or regenerative flares. The improved specificity of AFP-L3 and PIVKA-II has prompted their inclusion in regional guidelines, particularly in East Asia, where triple-marker panels are increasingly standard.
Beyond detection, AFP and its isoforms are powerful prognostic indicators. Pretreatment AFP levels correlate with tumor burden, vascular invasion, and overall survival, and the kinetics of AFP decline after locoregional or systemic therapy are widely used to monitor treatment response and to detect early recurrence after resection or transplantation. The Milan criteria, which incorporate AFP thresholds in several modified versions, illustrate the practical importance of biomarker-based risk stratification in transplant eligibility decisions. Together, these applications position AFP as one of the few serum analyms in oncology that informs nearly every stage of the disease continuum.
AFP in the Tumor Microenvironment and Therapeutic Era
A growing body of evidence indicates that AFP is not merely a passive readout of tumor burden but an active participant in shaping the immunosuppressive liver tumor microenvironment. AFP has been shown to impair dendritic cell maturation, suppress T-cell proliferation, and promote the expansion of regulatory T cells, collectively contributing to immune evasion by malignant hepatocytes. Recent reviews have highlighted how tumor-derived AFP acts in an autocrine and paracrine manner to support cancer stem-like cell populations and to modulate the activity of tumor-associated macrophages and myeloid-derived suppressor cells. This dual identity—as biomarker and as biological effector—has stimulated interest in AFP as a potential therapeutic target, including AFP-directed vaccines, antibody-drug conjugates, and T-cell receptor-engineered cellular therapies.
The advent of immune checkpoint inhibitor-based combination therapies, exemplified by the atezolizumab plus bevacizumab regimen that has become a new first-line standard for unresectable HCC, has further elevated the importance of baseline biomarker profiling. Pretreatment AFP levels are now used in clinical trial stratification, and dynamic changes in AFP and PIVKA-II during therapy are being explored as pharmacodynamic biomarkers. In this new therapeutic era, the ability to measure AFP together with a panel of immunologically relevant analytes is becoming essential for both research and patient management.
Frequently Asked Questions (FAQs)
AFP-L3 is the fucosylated isoform of AFP, identified by its binding to the lectin Lens culinaris agglutinin. It is produced preferentially by malignant hepatocytes and improves specificity for HCC, particularly when total AFP is only modestly elevated. PIVKA-II (also called des-γ-carboxy prothrombin, DCP) is an abnormal prothrombin generated by HCC cells and is a completely separate protein from AFP. While total AFP reflects the overall burden of AFP-producing cells, AFP-L3 captures aberrant glycosylation and PIVKA-II reflects dysfunctional vitamin K-dependent carboxylation, providing complementary information.
Serial AFP measurements are used to assess response to locoregional therapies, including ablation, transarterial chemoembolization, and radiotherapy, as well as to systemic therapies. A declining AFP level after treatment is generally associated with tumor response, while a rising AFP often signals progression or recurrence. In transplantation, pre-transplant AFP levels and post-transplant AFP kinetics inform decisions about transplant eligibility and post-transplant surveillance. PIVKA-II is increasingly used in parallel for the same purposes.
Yes. Protein arrays are well suited to AFP-related research because they enable parallel, quantitative measurement of AFP, AFP-L3, PIVKA-II, inflammatory cytokines, and immune-related analytes from a single small-volume sample. This makes it possible to design integrated biomarker panels that reflect both the tumor itself and the surrounding inflammatory and immunological milieu, supporting studies of HCC biology, treatment response, and biomarker discovery.
Total AFP has limited sensitivity for very small or early-stage tumors and can be elevated in non-malignant conditions such as active hepatitis or regenerative flares. AFP-L3 and PIVKA-II improve performance but are still imperfect, particularly for very early disease. The biology of HCC is highly heterogeneous, and no single marker captures all clinically relevant phenotypes. Multi-marker strategies, integration with imaging, and incorporation of inflammation- and immune-related analytes are the most active areas of current investigation to overcome these limitations.
References
- Chen T, et al. AFP promotes HCC progression by suppressing the HuR-mediated Fas/FADD apoptotic pathway. Cell Death Dis. 2020 Oct 2;11(10):822.
- Yamashita T, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008 Mar 1;68(5):1451-61.
- Lu Y, et al. The role of alpha-fetoprotein in the tumor microenvironment of hepatocellular carcinoma. Front Oncol. 2024 Apr 10;14:1363695.
- Galle PR, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019 Dec;39(12):2214-2229.
- Kim DY, et al. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region. Clin Mol Hepatol. 2023 Apr;29(2):277-292.